Why This Summit Is Unmissable for Biotech Leaders
Advance Your RNA-Targeted Small Molecule Programs With Insights From Industry Peers.
The RNA-targeted small molecule landscape is reaching a crucial inflection point. With increasing clinical validation, growing pharma interest, and significant scientific innovation, biotech leaders must determine where to invest, how to differentiate their platforms, and what it will take to successfully progress programs toward commercialization.
This summit brings together the founders, CSOs, CEOs, platform innovators, and strategic decision-makers shaping the future of RNA-targeted therapeutics.
Challenges We Help Solve
Differentiating Your Platform in a Crowded Market
Understand how successful companies are defining clear competitive advantages and attracting strategic attention.
Advancing From Discovery to Clinical Validation
Learn how leaders are overcoming key scientific and operational hurdles as programs mature.
Securing Strategic Partnerships & Investment
Benchmark approaches for attracting pharma partnerships, investors, and collaborators.
Staying Ahead of the Competitive Landscape
Gain visibility into emerging technologies, companies, and therapeutic opportunities.
Identifying the Next Major Growth Opportunities
Understand which scientific and commercial trends are likely to shape the field over the next five years.
Priority Sessions for Biotech Leaders
Learning From the Companies Driving Clinical Progress
Conference Day One: Mechanistic Insights into Splicing Modulation to Define RNA-Small Molecule Interactions & Unlock Targetable Splice Sequences
Speaker:
- Christopher Trotta, Senior Vice President of Discovery Biology, PTC Therapeutics
Gain insight into how one of the most established organizations in the field is expanding targetable RNA sequences and progressing therapeutically relevant programs.
Understanding How the Landscape Is Evolving Beyond Splice Modulation
Conference Day Two: RNA Methyltransferase Inhibition Validates Epitranscriptomic Regulation as a Novel Approach in the Treatment of Solid Tumors
Speaker:
- Andrea Casazza, Head of Cancer Biology, EPICS Therapeutics
Explore how novel mechanisms and therapeutic approaches are expanding the commercial opportunity within RNA-targeted drug discovery.
Preparing for the Future of RNA-Targeted Drug Discovery
Conference Day Two: Panel Discussion: Establishing RNA-Targeted Small Molecules as a Generalizable Drug Modality
Speaker:
- Sridhar Narayan, Vice President, Medicinal Chemistry, ReviR Therapeutics
Hear senior leaders discuss future growth opportunities, remaining barriers to success, and the evidence needed to unlock wider adoption and investment across the field.
Benchmark Your Strategy Against Peers
Questions you could ask your peers to benchmark against them:
How are leading companies differentiating their RNA-targeting platforms?
What milestones are pharma partners looking for?
Which modalities are attracting the greatest investment?
How are companies balancing platform development versus asset progression?
What will define success in RNA-targeted therapeutics over the next 3–5 years?
What Past Attendees Say
The RNA conference provides the best opportunity to engage with the largest number of RNA-targeting companies, most of whom attend other conferences but rarely the same ones.
I greatly enjoyed the panel discussions, which were highly interactive and offered different perspectives from leaders in the field. It was particularly exciting to learn about the new chemical entities currently in clinical trials, as well as the novel strategies for RNA modulation and tools for discovery. Overall, the summit was both informative and inspiring, giving me valuable insights and ideas that I can bring back to my own work.
Explore the Agenda
Hear the latest industry advances in RNA target selection, structure-guided design, selective modulation and translational strategies across the full RNA-targeted small molecule pipeline and during our packed agenda, interactive roundtables, and panel discussions.
Partner With Us
Position yourself alongside other leading solution providers to ensure your brand is at the heart of biopharma deals.
Join Biopharma Experts
Connect with RNA-targeted small molecule leaders across discovery, preclinical and clinical development during our dedicated networking sessions to exchange insights, build collaborations and strengthen decisions from target selection to therapeutic impact.